nmd-pharma-treatment-44.html
Novo Annual Review 2016
45 / 71
a seed investment in
corwave
heart failure is one of the leading causes of death globally. with their unique blood
pump
technology
, paris- based medtech,
corwave
is working to reverse these critical figures. novo seeds is on board as part of a eur 15.5 million series b fundraising. h eart transplant is the most effective treatment for end-stage heart failure. however, such an intervention is only relevant or possible in a minority of cases. the majority of cardiac patients get a mechanical
pump
implanted. left ventricular assist devices (lvads) are mechanical
pump
s that are implanted below the native heart. they can restore blood flow to normal levels and correct the main symptoms associated with heart failure. lvads can add up to 10 years of additional life to patients. need for new generation blood
pump
s the problem with current
pump
technologies ? based on rotor technologies ? is that they create a non-physiological flow; they are also associated with a high risk of serious adverse events. after two years of support, more than 80% of patients will be affected by at least one debilitating complication caused by the
pump
itself ? mainly stroke, bleeding or infection. the french medtech company,
corwave
has developed a disruptive
technology
that could overcome the limitations of the current rotary
pump
lvads. an innovative motion membrane
corwave
was founded in 2011 by paris-based incubator, md start. the company won the world innovation challenge in 2016. the
corwave
lvad utilises an undulating disc wave
pump
ing mechanism, which replaces the high speed, high shear impeller of the current continuous flow rotary
pump
s. this mechanism causes much less trauma to the blood, reducing clotting and bleeding complications. the high frequency actuation of the
corwave
pump
generates a pulsatile flow that mimics the action of the native heart, whereas current lvads provide only continuous flow with no significant pulsation, due to the high inertia of their rotors. in addition to low power consumption and small size, the
corwave
pump
combines total implantability with the incorporation of benefits from a wireless energy transfer system. support from an international syndicate
corwave
has recently raised a eur 15.5 million in a financing round led by novo seeds, with the support of an international syndicate of new and existing investors, including ysios capital, sofinnova partners, bpifrance and seventures. with this funding in place,
corwave
now has the resources to prepare their lvad
pump
for the first-in-man study, bringing this pioneering
technology
into the hands of clinicians. fast facts on
corwave
?s ?fish tail?
technology
the wave membrane
technology
developed by
corwave
is a unique and disruptive
technology
protected by seven patent families. it is the result of more than 10 years of research led by academic laboratories and ams r&d. this unique ?fish tail?
technology
enables a gentle
pump
ing of the blood, and
corwave
?s lvad has the potential to become the only fully pulsatile device on the market, mimicking heart beats. ?we have proven through in vitro physiologic models and in vivo experiments that the
corwave
pump
can faithfully replicate the native heart pulse and successfully restore blood circulation. our talented team of engineers and scientists is now working hard to take the
technology
to the next stages: turn our
pump
into a qualified product and bring it to patients.? louis de lillers, ceo 45 novo seeds
project-focuses-clinical-46.html
